Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S(®) coated modified release formulations of mesalamine, such as Asacol(®), remain among the most popular choices. We here review the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Doherty, Glen A, Peppercorn, Mark A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108647/
https://www.ncbi.nlm.nih.gov/pubmed/21694838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108647/
https://www.ncbi.nlm.nih.gov/pubmed/21694838

Ejemplares similares